Contact Info

Licensing Around the World

Check out a map of NIH Active Licenses around the world. To see only NIAID licenses, select NIAID from the Institute/Center drop-down list and click Submit. You can also filter the map by fiscal year and country.

Related Links

View a list of links for more information about technology development.

Javascript Error

Your browser JavaScript is turned off causing certain features of the NIAID Institute of Allergy and Infectious Diseases web site to work incorrectly. Please visit your browser settings and turn JavaScript on.
Read more information on enabling JavaScript.

Technology Transfer and Intellectual Property

NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research. But it's a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health. The Technology Transfer and Intellectual Property Office facilitates collaborative relationships between NIAID investigators and the broader scientific community.

NIAID and Gilead Sciences, Inc., signed a CRADA to study the safety and efficacy of Gilead's proprietary compounds including GS7977, GS5885, and GS9669 to treat hepatitis C/HIV co-infection and HCV infection in hard-to-treat populations and identification of the clinical and biological correlates associated with treatment response. NIAID principal investigator: Shyamasundaran Kottilil M.D., Ph.D.